Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunHER: SC vs IV Trastuzumab in HER2+ Breast Cancer
NCT03144947Phase 2Unknown
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Nov 2016
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Stromal Tumor Infiltrating Lymphocytes Rate at 6 months. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03144947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144947.